Rexahn seeks entry into sexual dysfunction market

At least that's the hairpin that Rockville's Rexahn Pharmaceuticals is bewitching as it steers its ED treatment candidate completed clinical trials, with its sights allot on a lucrative worldwide market. Unlike ED treatments promptly on the market, Zoraxel works by acting on the brain, said CEO Chang Ahn in commenting on recently announced confident results from a episode 2a clinical study.

These clinical scan results are appropriate encouraging, and substantiate our position that the budgeted of ED treatment lies in compounds that feature on the brain (central fussy system) and directions the underlying condition," Ahn said in a statement. This is a departure from the contemporary average of care, PDE-5 inhibitors, which peerless intent extreme organ erectile function. We surmise that Zoraxel has the future to authorize a latest morals of anxiety for sexual dysfunction."

The incidence of ED is facund and growing, according to Rexahn. It affects up to 30 million Americans, with 52 percent of men between 40 and 70 reporting disagreement with erectile function. By 2025, it is estimated that 322 million men globally testament suffer from some measure of sexual dysfunction.

The is significant, too. Latest year, sales of Pfizer's Viagra, Eli Lilly's Cialis and Bayer's Levitra - the "Big Three" for ED, so to affirm - totaled $3.8 billion, with their sales up from 7 percent to 19 percent, when adjusted for currency alternate fluctuations. The sheet 2a analysis was designed to degree Zoraxel's safety and preliminary efficacy in men 18 to 65 with ED.

The men showed improved erectile service as measured by changes over the "International Index of Erectile Function," plus meaningful improvement in quality-of-life measures, over the eight-week period, Rexahn said. The business is any more planning a event 2b trial.

Based on the original preliminary evaluation results, "Zoraxel clearly has the imaginable to be a safer and exceeding capable alternative to currently marketed drugs for ED," said urologist Myron Murdock, one of the glance at investigators. The narcotic doesn't retain some of the side belongings of other ED treatments, such as heart, hearing and eye problems, the society says. Mainly rats seem to drink in Zoraxel, too, according to dewy results from a Dutch study.

Utrecht University researchers reported that the important compound in Zoraxel produced a "remarkable" burgeoning in sexual enterprise in rats. The announce institute that Zoraxel exerts brawny "pro-sexual tool in masculine rats, an aftereffect amplified after 14 days of treatment." Results suggested that Zoraxel is efficacious in treating both drug- and non-drug-related sexual dysfunction. Alive with psychotropics, expressly antidepressants and selective serotonin reuptake inhibitors are commonly associated with unwanted sexual side effects.

Sexual disturbances allow for libido, erection and orgasm problems. This recite reveals very evidence that Zoraxel can be an effectual treatment for drug related and non-drug related sexual dysfunction, and is capable of improving sexual servicing with minimal side-effects," said Doeg Joong Kim Sr., Rexahn's employer of proof and development.

Rexahn said it received first-class dope on another front, too, as the NYSE Amex has usual its compliance plan, which was submitted in March. In February, the modify told Rexahn that it was noncompliant with decided listing requirements, as it reported enmesh losses in its five most latest fiscal senility and had fairness below $6 million.

At the end week, the moderate granted Rexahn an space until Aug. 24, 2010, to regain compliance. In other Maryland bioscience news: The NYSE Amex has warned RegeneRx Biopharmaceuticals that it's running afoul of the corresponding listing requirements as Rexahn: stockholders' equity of less than $6 million and catch losses in the ended five years.

The Bethesda company, which is developing treatments to repair skin, eye and cardiovascular tissue, plus a drug for cystic fibrosis, said it plans to string a compliance pathway by the May 25 deadline. RegeneRx did announcement some besides encouraging news: It received an Australian patent for treating eye disorders with its thymosin beta 4 compound.

The patent, which expires in 2022, includes using the product to treat curative related to eye surgery such as Lasik. BioReliance Corp. Rockville, which provides business agreement services to the pharmaceutical and biopharmaceutical industries, is enlarging its global presence, opening a liaison employment in Bangalore, India.

The 62-year-old firm besides has help in Scotland and Japan, with expanded than 650 employees. To date, we acquire successfully served the Indian biopharmaceutical marketplace fini our UK offices," said Jarlath Keating, senior director of sales, North America and Asia Pacific, in a statement.

However, at this era when the Indian biomanufacturing bazaar is growing in combat and reach, it is fine that having a district presence will be the top step in which to block our clients for the future.

We bad eye forward to working added closely with the businesses in this critical region and assisting them in growing their global presence."